Ingrid YiChun Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ingrid YiChun Liu has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
Pavithra Suresh
Institute of Medical Sciences, College of Medicine, Tzu Chi University, Hualien, Taiwan
8 shared publications- Sarayut Phasuk
Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan
7 shared publications Peeraporn Varinthra
Institute of Medical Sciences, College of Medicine, Tzu Chi University, Hualien, Taiwan
6 shared publicationsSupin Chompoopong
Department of Anatomy, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
6 shared publications- Peeraporn Varinthra
Institute of Medical Sciences, College of Medicine Tzu Chi University Hualien Taiwan
5 shared publications Tanita Pairojana
Institute of Medical Sciences, Tzu Chi University, Hualien City, Taiwan
5 shared publications
Latest Publications
- Open Access
- 17 April 2026
- Published by Wolters Kluwer Health in Tzu Chi Medical Journal
- Vol. 38 (3) , 263-274
Therapeutic advances in Alzheimer’s disease: Current strategies and future possibilities
A BSTRACT: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder causing memory, cognitive, and behavioral impairments in older adults and poses a major worldwide health challenge. The pathophysiology of AD is highly complex and multifactorial, arising from interrelated processes such as amyloid-β (Aβ) aggregation, tau hyperphosphorylation, synaptic dysfunction, neuroinflammation, mitochondrial impairment, and oxidative stress. In addition, both genetic predisposition and environmental or lifestyle factors play critical roles in disease susceptibility and progression. Despite decades of investigation, therapeutic options with robust disease-modifying potential remain limited. Based on published studies from 2021 to 2025, current treatments primarily focus on symptomatic management with cholinesterase inhibitors, N-methyl-D-aspartate receptor antagonists, and combined therapies, complemented by nonpharmacological interventions to support cognition and quality of life. Recently, advances in disease-modifying strategies, particularly monoclonal antibodies targeting Aβ, tau-directed therapies, and approaches modulating neuroinflammation, have generated cautious optimism for shifting the treatment paradigm. Importantly, emerging evidence suggests that specific herbal extracts with antioxidant, anti-inflammatory, and neuroprotective properties may serve as promising adjuncts to conventional therapy. Effective long-term management of AD may ultimately require multimodal strategies that integrate pharmacological, herbal, and lifestyle interventions with precision medicine approaches guided by biomarkers and neuroimaging. This minireview summarizes current therapeutic strategies, emerging advances, and persistent challenges, while highlighting future directions to enable earlier intervention and more effective modulation of disease progression.
- 17 April 2026
- Published by Wolters Kluwer Health in Tzu Chi Medical Journal
- Vol. 38 (3) , 263-274
Open AccessTherapeutic advances in Alzheimer’s disease: Current strategies and future possibilities
A BSTRACT: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder causing memory, cognitive, and behavioral impairments in older adults and poses a major worldwide health challenge. The pathophysiology of AD is highly complex and multifactorial, arising from interrelated processes such as amyloid-β (Aβ) aggregation, tau hyperphosphorylation, synaptic dysfunction, neuroinflammation, mitochondrial impairment, and oxidative stress. In addition, both genetic predisposition and environmental or lifestyle factors play critical roles in disease susceptibility and progression. Despite decades of investigation, therapeutic options with robust disease-modifying potential remain limited. Based on published studies from 2021 to 2025, current treatments primarily focus on symptomatic management with cholinesterase inhibitors, N-methyl-D-aspartate receptor antagonists, and combined therapies, complemented by nonpharmacological interventions to support cognition and quality of life. Recently, advances in disease-modifying strategies, particularly monoclonal antibodies targeting Aβ, tau-directed therapies, and approaches modulating neuroinflammation, have generated cautious optimism for shifting the treatment paradigm. Importantly, emerging evidence suggests that specific herbal extracts with antioxidant, anti-inflammatory, and neuroprotective properties may serve as promising adjuncts to conventional therapy. Effective long-term management of AD may ultimately require multimodal strategies that integrate pharmacological, herbal, and lifestyle interventions with precision medicine approaches guided by biomarkers and neuroimaging. This minireview summarizes current therapeutic strategies, emerging advances, and persistent challenges, while highlighting future directions to enable earlier intervention and more effective modulation of disease progression.
- Open Access
- 9 October 2025
- Published by Elsevier in Neurotherapeutics
- Vol. 22 (6) , e00761
Activation of GABA transmission by clonazepam reverses the autistic-like phenotypes of the Cav3.2 knockout mice
- 9 October 2025
- Published by Elsevier in Neurotherapeutics
- Vol. 22 (6) , e00761
Open AccessActivation of GABA transmission by clonazepam reverses the autistic-like phenotypes of the Cav3.2 knockout mice
- Open Access
- 31 July 2025
- Published by Springer Nature in Molecular Medicine
- Vol. 31 (1) , 1-19
Coniferaldehyde reverses 3-nitropropionic acid-induced Huntington’s disease pathologies via PKM2 restoration and JAK2/STAT3 inhibition
Background: Huntington’s disease (HD) is a fatal neurodegenerative disorder characterized by progressive motor decline and neuronal loss, with no curative disease-modifying therapies available. The mitochondrial toxin 3-nitropropionic acid (3-NP) is widely used to model HD-like pathologies. We investigated the therapeutic potential of coniferaldehyde (CFA), a natural phenolic compound with anti-inflammatory, antioxidant, and anti-radical properties, against 3-NP-induced neurodegeneration. Given the roles of oxidative stress, metabolic dysfunction, and neuroinflammation in HD, we hypothesize that CFA exerts neuroprotection by attenuating these processes via the Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway - a novel target for CFA in HD. Methods: Neurological and behavioral deficits were assessed via neurological assessment scaling, rotarod, and open field tests. Nissl staining was performed to evaluate neuronal damage in the motor cortex and striatum. Dihydroethidium staining (DHE) was used to measure reactive oxygen species (ROS) levels, and the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay was conducted to detect apoptosis. Western blot assay and immunofluorescence staining were used to examine CFA’s effect. Additionally, molecular docking was performed to analyze CFA’s interaction with STAT3. Results: CFA treatment significantly improved motor function, preserved neuronal architecture, and reduced apoptosis, as confirmed by Nissl and TUNEL staining. CFA also decreased ROS levels and restored pyruvate kinase M2 (PKM2) expression, a key regulator of metabolic homeostasis. Consistently, CFA attenuated neuroinflammation by suppressing Glial Fibrillary Acidic Protein (GFAP) expression and proinflammatory cytokines Interleukin-6 (IL-6) and Interleukin-1 beta (IL-1β). Molecular docking studies revealed a strong binding affinity between CFA and STAT3, and western blot analysis showed reduced phosphorylation of STAT3, indicating modulation of the JAK2/STAT3 signaling pathway. Conclusion: These findings demonstrate that CFA modulates oxidative, PKM2-mediated metabolic, and inflammatory pathways through the JAK2/STAT3 axis, enhancing motor function and neuronal survival in a 3-NP model of HD. This multi-targeted mechanism highlights its potential as a disease-modifying therapy for advancing therapeutic strategies in HD and related neurodegenerative disorders. Graphical Neuroprotective mechanism of CFA in a 3-NP-induced HD model. 3-NP induces HD-like pathology in the motor cortex and striatum by inhibiting succinate dehydrogenase (Complex II), leading to ATP depletion, increased reactive oxygen species (ROS), neuroinflammation, apoptosis, PKM2 dysregulation, neurological impairments, and motor deficits. CFA treatment attenuates these pathological processes by reducing ROS and apoptosis, restoring PKM2 expression, and modulating glial activation and proinflammatory cytokines (IL-6 and IL-1β). In silico docking and in vivo analyses further show that CFA reduces phosphorylation of STAT3, suggesting suppression of the JAK2/STAT3 pathway as a key mechanism of action. CFA promotes neurological and motor improvement, metabolic, and inflammatory homeostasis, supporting its potential as a disease-modifying therapeutic for HD.
- 31 July 2025
- Published by Springer Nature in Molecular Medicine
- Vol. 31 (1) , 1-19
Open AccessConiferaldehyde reverses 3-nitropropionic acid-induced Huntington’s disease pathologies via PKM2 restoration and JAK2/STAT3 inhibition
Background: Huntington’s disease (HD) is a fatal neurodegenerative disorder characterized by progressive motor decline and neuronal loss, with no curative disease-modifying therapies available. The mitochondrial toxin 3-nitropropionic acid (3-NP) is widely used to model HD-like pathologies. We investigated the therapeutic potential of coniferaldehyde (CFA), a natural phenolic compound with anti-inflammatory, antioxidant, and anti-radical properties, against 3-NP-induced neurodegeneration. Given the roles of oxidative stress, metabolic dysfunction, and neuroinflammation in HD, we hypothesize that CFA exerts neuroprotection by attenuating these processes via the Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) pathway - a novel target for CFA in HD. Methods: Neurological and behavioral deficits were assessed via neurological assessment scaling, rotarod, and open field tests. Nissl staining was performed to evaluate neuronal damage in the motor cortex and striatum. Dihydroethidium staining (DHE) was used to measure reactive oxygen species (ROS) levels, and the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay was conducted to detect apoptosis. Western blot assay and immunofluorescence staining were used to examine CFA’s effect. Additionally, molecular docking was performed to analyze CFA’s interaction with STAT3. Results: CFA treatment significantly improved motor function, preserved neuronal architecture, and reduced apoptosis, as confirmed by Nissl and TUNEL staining. CFA also decreased ROS levels and restored pyruvate kinase M2 (PKM2) expression, a key regulator of metabolic homeostasis. Consistently, CFA attenuated neuroinflammation by suppressing Glial Fibrillary Acidic Protein (GFAP) expression and proinflammatory cytokines Interleukin-6 (IL-6) and Interleukin-1 beta (IL-1β). Molecular docking studies revealed a strong binding affinity between CFA and STAT3, and western blot analysis showed reduced phosphorylation of STAT3, indicating modulation of the JAK2/STAT3 signaling pathway. Conclusion: These findings demonstrate that CFA modulates oxidative, PKM2-mediated metabolic, and inflammatory pathways through the JAK2/STAT3 axis, enhancing motor function and neuronal survival in a 3-NP model of HD. This multi-targeted mechanism highlights its potential as a disease-modifying therapy for advancing therapeutic strategies in HD and related neurodegenerative disorders. Graphical Neuroprotective mechanism of CFA in a 3-NP-induced HD model. 3-NP induces HD-like pathology in the motor cortex and striatum by inhibiting succinate dehydrogenase (Complex II), leading to ATP depletion, increased reactive oxygen species (ROS), neuroinflammation, apoptosis, PKM2 dysregulation, neurological impairments, and motor deficits. CFA treatment attenuates these pathological processes by reducing ROS and apoptosis, restoring PKM2 expression, and modulating glial activation and proinflammatory cytokines (IL-6 and IL-1β). In silico docking and in vivo analyses further show that CFA reduces phosphorylation of STAT3, suggesting suppression of the JAK2/STAT3 pathway as a key mechanism of action. CFA promotes neurological and motor improvement, metabolic, and inflammatory homeostasis, supporting its potential as a disease-modifying therapeutic for HD.
- Open Access
- 2 June 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (6) , e70607
GABAergic Signaling Underlying REM Sleep Deprivation‐Induced Spatial Working Memory Deficits
Introduction: Declining spatial working memory (WM) is an early hallmark of Alzheimer's disease (AD). Sleep disturbance exacerbates spatial WM and increases AD risk. The GABAergic system, crucial for sleep regulation, may mediate this link. We thus investigate the relationship between spatial WM and hippocampal GABAergic signaling during rapid eye movement sleep deprivation (REM‐SD) in AD model mice.Methods: We assessed spatial and non‐spatial WM, locomotor activity, and anxiety‐like behavior in 6‐month‐old triple transgenic (3xTg) AD mice and wild‐type (WT) controls, with and without REM‐SD (5 days, 4 h/day). We then used immunofluorescence to quantify GABAAα1, GABABR1, GAD67, and GABA levels in the prefrontal cortex (PFC) and hippocampus and analyze the correlations with behavioral outcomes.Results: REM‐SD increased locomotor activity, reduced anxiety‐like behavior, and improved non‐spatial WM in 3xTg‐AD mice. Conversely, REM‐SD impaired spatial WM in WT mice, which was also demonstrated in 3xTg‐AD mice. Increased hippocampal GABA levels are correlated with improved non‐spatial WM in 3xTg+SD mice. In contrast, impaired spatial WM in WT+SD mice was associated with elevated hippocampal GABA and GABABR1, decreased hippocampal GAD67, and reduced PFC GABA levels. Notably, spatial WM in 3xTg+SD and 3xTg control mice related to increased GABAAα1 in the PFC and hippocampus and GAD67 in hippocampal CA1, along with decreased GABABR1 and GAD67 in the dentate gyrus.Conclusion: REM‐SD‐induced alterations in WM performance are linked to GABAergic signaling changes in the PFC and hippocampus, with distinct patterns in WT and 3xTg‐AD mice. This study provides insight into AD pathologies and potential therapeutic targets for sleep‐related cognitive impairments.
- 2 June 2025
- Published by Wiley in Brain and Behavior
- Vol. 15 (6) , e70607
Open AccessGABAergic Signaling Underlying REM Sleep Deprivation‐Induced Spatial Working Memory Deficits
Introduction: Declining spatial working memory (WM) is an early hallmark of Alzheimer's disease (AD). Sleep disturbance exacerbates spatial WM and increases AD risk. The GABAergic system, crucial for sleep regulation, may mediate this link. We thus investigate the relationship between spatial WM and hippocampal GABAergic signaling during rapid eye movement sleep deprivation (REM‐SD) in AD model mice.Methods: We assessed spatial and non‐spatial WM, locomotor activity, and anxiety‐like behavior in 6‐month‐old triple transgenic (3xTg) AD mice and wild‐type (WT) controls, with and without REM‐SD (5 days, 4 h/day). We then used immunofluorescence to quantify GABAAα1, GABABR1, GAD67, and GABA levels in the prefrontal cortex (PFC) and hippocampus and analyze the correlations with behavioral outcomes.Results: REM‐SD increased locomotor activity, reduced anxiety‐like behavior, and improved non‐spatial WM in 3xTg‐AD mice. Conversely, REM‐SD impaired spatial WM in WT mice, which was also demonstrated in 3xTg‐AD mice. Increased hippocampal GABA levels are correlated with improved non‐spatial WM in 3xTg+SD mice. In contrast, impaired spatial WM in WT+SD mice was associated with elevated hippocampal GABA and GABABR1, decreased hippocampal GAD67, and reduced PFC GABA levels. Notably, spatial WM in 3xTg+SD and 3xTg control mice related to increased GABAAα1 in the PFC and hippocampus and GAD67 in hippocampal CA1, along with decreased GABABR1 and GAD67 in the dentate gyrus.Conclusion: REM‐SD‐induced alterations in WM performance are linked to GABAergic signaling changes in the PFC and hippocampus, with distinct patterns in WT and 3xTg‐AD mice. This study provides insight into AD pathologies and potential therapeutic targets for sleep‐related cognitive impairments.
- Open Access
- 22 August 2024
- Published by Wolters Kluwer Health in Tzu Chi Medical Journal
- Vol. 37 (1) , 1-9
The role of netrin G1-netrin-G-ligand-1 in schizophrenia
Schizophrenia (SCZ) is a chronic psychotic disorder that profoundly alters an individual’s perception of reality, resulting in abnormal behavior, cognitive deficits, thought distortions, and disorientation in emotions. Many complicated factors can lead to SCZ, and investigations are ongoing to understand the neurobiological underpinnings of this condition. Presynaptic Netrin G1 and its cognate partner postsynaptic Netrin-G-Ligand-1 (NGL-1) have been implicated in SCZ. This review article emphasized the structure and expression of Netrin G1/NGL-1 in the brain, its dysregulation in SCZ patients, and its role in synaptic plasticity, synaptic interaction, learning and memory, microglia neurotrophic activity, and possible signaling between Netrin G1/NGL-1, postsynaptic density protein 95, and cyclin-dependent kinase-like 5 in synaptic morphogenesis. Pharmaceutical targets and the potential use of Netrin G1/NGL-1 as treatment targets or biomarkers for SCZ were also discussed.
- 22 August 2024
- Published by Wolters Kluwer Health in Tzu Chi Medical Journal
- Vol. 37 (1) , 1-9
Open AccessThe role of netrin G1-netrin-G-ligand-1 in schizophrenia
Schizophrenia (SCZ) is a chronic psychotic disorder that profoundly alters an individual’s perception of reality, resulting in abnormal behavior, cognitive deficits, thought distortions, and disorientation in emotions. Many complicated factors can lead to SCZ, and investigations are ongoing to understand the neurobiological underpinnings of this condition. Presynaptic Netrin G1 and its cognate partner postsynaptic Netrin-G-Ligand-1 (NGL-1) have been implicated in SCZ. This review article emphasized the structure and expression of Netrin G1/NGL-1 in the brain, its dysregulation in SCZ patients, and its role in synaptic plasticity, synaptic interaction, learning and memory, microglia neurotrophic activity, and possible signaling between Netrin G1/NGL-1, postsynaptic density protein 95, and cyclin-dependent kinase-like 5 in synaptic morphogenesis. Pharmaceutical targets and the potential use of Netrin G1/NGL-1 as treatment targets or biomarkers for SCZ were also discussed.
- Open Access
- 26 March 2024
- Published by Wolters Kluwer Health in Tzu Chi Medical Journal
- Vol. 36 (2) , 103-109
The role of the GABAergic system on insomnia
Sleep is an essential activity for the survival of mammals. Good sleep quality helps promote the performance of daily functions. In contrast, insufficient sleep reduces the efficiency of daily activities, causes various chronic diseases like Alzheimer’s disease, and increases the risk of having accidents. The GABAergic system is the primary inhibitory neurotransmitter system in the central nervous system. It transits the gamma-aminobutyric acid (GABA) neurotransmitter via GABA A and GABA B receptors to counterbalance excitatory neurotransmitters, such as glutamate, noradrenaline, serotonin, acetylcholine, orexin, and dopamine, which release and increase arousal activities during sleep. Several studies emphasized that dysfunction of the GABAergic system is related to insomnia, the most prevalent sleep-related disorder. The GABAergic system comprises the GABA neurotransmitter, GABA receptors, GABA synthesis, and degradation. Many studies have demonstrated that GABA levels correlate with sleep quality, suggesting that modulating the GABAergic system may be a promising therapeutic approach for insomnia. In this article, we highlight the significance of sleep, the classification and pathology of insomnia, and the impact of the GABAergic system changes on sleep. In addition, we also review the medications that target the GABAergic systems for insomnia, including benzodiazepines (BZDs), non-BZDs, barbiturates, GABA supplements, and Chinese herbal medicines.
- 26 March 2024
- Published by Wolters Kluwer Health in Tzu Chi Medical Journal
- Vol. 36 (2) , 103-109
Open AccessThe role of the GABAergic system on insomnia
Sleep is an essential activity for the survival of mammals. Good sleep quality helps promote the performance of daily functions. In contrast, insufficient sleep reduces the efficiency of daily activities, causes various chronic diseases like Alzheimer’s disease, and increases the risk of having accidents. The GABAergic system is the primary inhibitory neurotransmitter system in the central nervous system. It transits the gamma-aminobutyric acid (GABA) neurotransmitter via GABA A and GABA B receptors to counterbalance excitatory neurotransmitters, such as glutamate, noradrenaline, serotonin, acetylcholine, orexin, and dopamine, which release and increase arousal activities during sleep. Several studies emphasized that dysfunction of the GABAergic system is related to insomnia, the most prevalent sleep-related disorder. The GABAergic system comprises the GABA neurotransmitter, GABA receptors, GABA synthesis, and degradation. Many studies have demonstrated that GABA levels correlate with sleep quality, suggesting that modulating the GABAergic system may be a promising therapeutic approach for insomnia. In this article, we highlight the significance of sleep, the classification and pathology of insomnia, and the impact of the GABAergic system changes on sleep. In addition, we also review the medications that target the GABAergic systems for insomnia, including benzodiazepines (BZDs), non-BZDs, barbiturates, GABA supplements, and Chinese herbal medicines.
- Open Access
- 5 September 2022
- Published by Medknow in Tzu Chi Medical Journal
- Vol. 35 (2) , 103-110
Anti-inflammatory and memory-enhancing properties of Chinese herbal extracts: The possible application in Alzheimer’s disease
Alzheimer’s disease (AD) is a progressive brain disease that causes cognitive impairment in seniors. The beta-amyloid (Aβ) deposition and intracellular neurofibrillary tangles are two pathological hallmarks of AD. The increase of AD hallmarks causes inflammatory response enhancement, reduction of synaptic plasticity, and impaired cognition. The percentage of the aging population is growing along with the number of AD patients; however, effective treatment of AD is still limited. Therefore, developing preventive and therapeutic drugs for AD with fewer adverse side effects is urgently needed. The crude extracts from herbs such as Centella asiatica, Dendrobium catenatum, Litsea cubeba, Nardostachys jatamansi, Convolvulus pluricaulis, Melissa officinalis, Magnolia officinalis, Withania somnifera, and Nigella sativa improved memory performance and reduced inflammation response in various diseases. In addition, herbal blends usually have minimum aversive effects and can be mixed into diet and served as nutritional supplements. Hence, it is promising to develop Chinese herbal extracts to prevent or treat early AD. This review article highlights the currently available treatments of AD and the therapeutic effects of a group of crude extracts from Chinese herbs that can prevent cognitive decline and reduce the excessive inflammatory response. The possible clinical use of these Chinese herbal extracts in AD is also discussed.
- 5 September 2022
- Published by Medknow in Tzu Chi Medical Journal
- Vol. 35 (2) , 103-110
Open AccessAnti-inflammatory and memory-enhancing properties of Chinese herbal extracts: The possible application in Alzheimer’s disease
Alzheimer’s disease (AD) is a progressive brain disease that causes cognitive impairment in seniors. The beta-amyloid (Aβ) deposition and intracellular neurofibrillary tangles are two pathological hallmarks of AD. The increase of AD hallmarks causes inflammatory response enhancement, reduction of synaptic plasticity, and impaired cognition. The percentage of the aging population is growing along with the number of AD patients; however, effective treatment of AD is still limited. Therefore, developing preventive and therapeutic drugs for AD with fewer adverse side effects is urgently needed. The crude extracts from herbs such as Centella asiatica, Dendrobium catenatum, Litsea cubeba, Nardostachys jatamansi, Convolvulus pluricaulis, Melissa officinalis, Magnolia officinalis, Withania somnifera, and Nigella sativa improved memory performance and reduced inflammation response in various diseases. In addition, herbal blends usually have minimum aversive effects and can be mixed into diet and served as nutritional supplements. Hence, it is promising to develop Chinese herbal extracts to prevent or treat early AD. This review article highlights the currently available treatments of AD and the therapeutic effects of a group of crude extracts from Chinese herbs that can prevent cognitive decline and reduce the excessive inflammatory response. The possible clinical use of these Chinese herbal extracts in AD is also discussed.
- Open Access
- 29 July 2022
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 14, 916904
Attenuation of HECT-E3 ligase expression rescued memory deficits in 3xTg-AD mice
Alzheimer's disease (AD) is one of the most common progressive neurodegenerative disorders that cause deterioration of cognitive functions. Recent studies suggested that the accumulation of inflammatory molecules and impaired protein degradation mechanisms might both play a critical role in the progression of AD. Autophagy is a major protein degradation pathway that can be controlled by several HECT-E3 ligases, which then regulates the expression of inflammatory molecules. E3 ubiquitin ligases are known to be upregulated in several neurodegenerative diseases. Here, we studied the expressional change of HECT-E3 ligase using M01 on autophagy and inflammasome pathways in the context of AD pathogenesis. Our results demonstrated that the M01 treatment reversed the working memory deficits in 3xTg-AD mice when examined with the T-maze and reversal learning with the Morris water maze. Additionally, the electrophysiology recordings indicated that M01 treatment enhanced the long-term potentiation in the hippocampus of 3xTg-AD mice. Together with the improved memory performance, the expression levels of the NLRP3 inflammasome protein were decreased. On the other hand, autophagy-related molecules were increased in the hippocampus of 3xTg-AD mice. Furthermore, the protein docking analysis indicated that the binding affinity of M01 to the WWP1 and NEDD4 E3 ligases was the highest among the HECT family members. The western blot analysis also confirmed the decreased expression level of NEDD4 protein in the M01-treated 3xTg-AD mice. Overall, our results demonstrate that the modulation of HECT-E3 ligase expression level can be used as a strategy to treat early memory deficits in AD by decreasing NLRP3 inflammasome molecules and increasing the autophagy pathway.
- 29 July 2022
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 14, 916904
Open AccessAttenuation of HECT-E3 ligase expression rescued memory deficits in 3xTg-AD mice
Alzheimer's disease (AD) is one of the most common progressive neurodegenerative disorders that cause deterioration of cognitive functions. Recent studies suggested that the accumulation of inflammatory molecules and impaired protein degradation mechanisms might both play a critical role in the progression of AD. Autophagy is a major protein degradation pathway that can be controlled by several HECT-E3 ligases, which then regulates the expression of inflammatory molecules. E3 ubiquitin ligases are known to be upregulated in several neurodegenerative diseases. Here, we studied the expressional change of HECT-E3 ligase using M01 on autophagy and inflammasome pathways in the context of AD pathogenesis. Our results demonstrated that the M01 treatment reversed the working memory deficits in 3xTg-AD mice when examined with the T-maze and reversal learning with the Morris water maze. Additionally, the electrophysiology recordings indicated that M01 treatment enhanced the long-term potentiation in the hippocampus of 3xTg-AD mice. Together with the improved memory performance, the expression levels of the NLRP3 inflammasome protein were decreased. On the other hand, autophagy-related molecules were increased in the hippocampus of 3xTg-AD mice. Furthermore, the protein docking analysis indicated that the binding affinity of M01 to the WWP1 and NEDD4 E3 ligases was the highest among the HECT family members. The western blot analysis also confirmed the decreased expression level of NEDD4 protein in the M01-treated 3xTg-AD mice. Overall, our results demonstrate that the modulation of HECT-E3 ligase expression level can be used as a strategy to treat early memory deficits in AD by decreasing NLRP3 inflammasome molecules and increasing the autophagy pathway.
- Open Access
- 19 June 2022
- Published by MDPI AG in Antioxidants
- Vol. 11 (6) , 1201
Behavioral and Synaptic Phenotypes of Female Prdx6−/− Mice
Peroxiredoxin 6 (PRDX6) is expressed throughout the brain, including the hippocampus, where it plays a potential role in synaptic regulation and forming emotional and spatial memories. PRDX6 is predominantly detected in the female mouse’s hippocampus; thus, we investigate the effect of the Prdx6 gene on behavioral phenotypes and synaptic functions using female Prdx6 knockout (Prdx6−/−) mice. Our results demonstrate that female Prdx6−/− mice exhibited anxiety-like behavior, enhanced contextual fear memory, and impaired spatial memory. We also found increased, paired–pulse facilitation ratios, and decreased long-term potentiation (LTP) in the hippocampal region of these female Prdx6−/− mice. The present study helps to understand better the PRDX6’s role in emotional response and spatial memory formation in female mice.
- 19 June 2022
- Published by MDPI AG in Antioxidants
- Vol. 11 (6) , 1201
Open AccessBehavioral and Synaptic Phenotypes of Female Prdx6−/− Mice
Peroxiredoxin 6 (PRDX6) is expressed throughout the brain, including the hippocampus, where it plays a potential role in synaptic regulation and forming emotional and spatial memories. PRDX6 is predominantly detected in the female mouse’s hippocampus; thus, we investigate the effect of the Prdx6 gene on behavioral phenotypes and synaptic functions using female Prdx6 knockout (Prdx6−/−) mice. Our results demonstrate that female Prdx6−/− mice exhibited anxiety-like behavior, enhanced contextual fear memory, and impaired spatial memory. We also found increased, paired–pulse facilitation ratios, and decreased long-term potentiation (LTP) in the hippocampal region of these female Prdx6−/− mice. The present study helps to understand better the PRDX6’s role in emotional response and spatial memory formation in female mice.